These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38606104)

  • 1. Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review.
    Ma Y; Shi X; Zhao K; Hu S; Shi Y; Jiang Y; Liu Y; Lu L; Chang Y; Zhou F; Dai Y; Wu Z; Li S; Qian Z; Xu X; Li C; Shen B; Zhou G; Chen C; Wang X; Feng J
    Front Oncol; 2024; 14():1328844. PubMed ID: 38606104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Retreatment of Metastatic Triple-negative Breast Cancer With Immune Checkpoint Inhibitors and Chemotherapy.
    Nozaki Y; Yamamuro M; Tanaka N; Kamo N; Konishi J
    Cancer Diagn Progn; 2023; 3(3):387-391. PubMed ID: 37168973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
    Krasniqi E; Pizzuti L; Valerio MR; Capomolla E; Botti C; Sanguineti G; Marchetti P; Anselmi E; Tomao S; Giordano A; Ficorella C; Cannita K; Livi L; Meattini I; Mauri M; Greco F; Veltri EM; Michelotti A; Moscetti L; Giotta F; Lorusso V; Paris I; Tomao F; Santini D; Tonini G; Villa A; Gebbia V; Gamucci T; Ciliberto G; Sperduti I; Mazzotta M; Barba M; Vici P
    Int J Med Sci; 2021; 18(10):2245-2250. PubMed ID: 33859534
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
    Mougalian SS; Copher R; Kish JK; McAllister L; Wang Z; Broscious M; Garofalo D; Radtchenko J; Feinberg BA
    Cancer Med; 2018 Sep; 7(9):4371-4378. PubMed ID: 30066497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.
    Tolaney SM; Kalinsky K; Kaklamani VG; D'Adamo DR; Aktan G; Tsai ML; O'Regan RM; Kaufman PA; Wilks ST; Andreopoulou E; Patt DA; Yuan Y; Wang G; Savulsky C; Xing D; Kleynerman E; Karantza V; Diab S
    Clin Cancer Res; 2021 Jun; 27(11):3061-3068. PubMed ID: 33727258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathological and clinical landscape of refractory metastatic triple negative breast cancer: a narrative review.
    Jiang MP; Huang X; Yin YM; Tang JH
    Ann Transl Med; 2022 Aug; 10(16):907. PubMed ID: 36111045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.
    Sun H; Bu F; Li L; Zhang X; Xin X; Yan J; Huang T
    Ann Pharmacother; 2024 Apr; 58(4):349-359. PubMed ID: 37488978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
    Chabot I; Zhao Q; Su Y
    Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-containing regimens for triple-negative metastatic breast cancer.
    Egger SJ; Chan MMK; Luo Q; Wilcken N
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013750. PubMed ID: 33084020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study.
    Puhalla S; Wilks S; Brufsky AM; O'Shaughnessy J; Schwartzberg LS; Berrak E; Song J; Vahdat L
    Breast Cancer (Dove Med Press); 2016; 8():231-239. PubMed ID: 27994483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer.
    Ghebeh H; Elshenawy MA; AlSayed AD; Al-Tweigeri T
    Immunotherapy; 2022 Mar; 14(4):189-199. PubMed ID: 34984928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).
    Kim SH; Im SA; Suh KJ; Lee KH; Kim MH; Sohn J; Park YH; Kim JY; Jeong JH; Lee KE; Choi IS; Park KH; Kim HJ; Cho EK; Park SY; Kim M; Kim JH
    Eur J Cancer; 2023 Dec; 195():113386. PubMed ID: 37890351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
    Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
    Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants.
    Wu Q; Wu C; Xie X
    J Immunother; 2023 Feb-Mar 01; 46(2):29-42. PubMed ID: 36378154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.
    Kim H; Kim HJ; Kim H; Kim HR; Jo H; Hong J; Kim R; Kim JY; Ahn JS; Im YH; Lee SK; Kim H; Shin SY; Park YH
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.